Durect corporation announces u.s. fda approval of posimir® for post-surgical pain reduction for up to 72 hours following arthroscopic subacromial decompression

Cupertino, calif., feb. 2, 2021 /prnewswire/ -- durect corporation (nasdaq: drrx) today announced that the u.s. food and drug administration (fda) has approved posimir® (bupivacaine solution) for infiltration use in adults for administration into the subacromial space under direct...
DRRX Ratings Summary
DRRX Quant Ranking